Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.36 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4206914 | 0.92 | MAPT (0.54) | MAPTKDM4EHPGDNPSR1RECQL | |
| SCHEMBL19734888 | 0.82 | KDM4E (0.44) | MAPTKDM4EHPGDNPSR1RECQL | |
| SCHEMBL3654974 | 0.81 | MAPT (0.48) | MAPTKDM4EHPGDNPSR1RECQL | |
| SCHEMBL6255126 | 0.78 | RECQL (0.37) | MAPTKDM4EHPGDNPSR1RECQL | |
| SCHEMBL8317724 | 0.76 | ALDH1A1 (0.57) | MAPTKDM4EHPGDNPSR1RECQL | |
| SCHEMBL6265005 | 0.73 | TLR8 (0.64) | MAPTKDM4EHPGDNPSR1ALDH1A1 | |
| SCHEMBL4658289 | 0.71 | KCNH2 (0.38) | MAPTKDM4EHPGDNPSR1RECQL | |
| SCHEMBL1539841 | 0.71 | KDM4E (0.43) | MAPTKDM4EHPGDNPSR1RECQL | |
| SCHEMBL416757 | 0.70 | HPGD (0.54) | MAPTKDM4EHPGDNPSR1MAPK1 | |
| SCHEMBL21444633 | 0.70 | MAPK1 (0.53) | MAPTKDM4EHPGDNPSR1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883500-B2 | Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy | NORTHEASTERN UNIVERSITY (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140155401-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-05 | — | — | US | disclosed |
| US-8703934-B2 | Substituted 4-amino-3,5-dicyano-2-thiopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| US-8653109-B2 | Substituted bipyridine derivatives and their use as adenosine receptor ligands | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| EP-2099788-B1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER IP GMBH (DE) | 2013-03-06 | — | — | EP | disclosed |
| US-8304412-B2 | Cyclically substituted 3,5-dicyano-2-thiopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| EP-2099781-B1 | SUBSTITUTED 4-AMINO-3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-7825255-B2 | Adenosine receptor selective modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-02 | — | — | US | disclosed |
| WO-2010065959-A1 | METHOD OF PREPARING ADENOSINE-RESISTANT ANTI-TUMOR T LYMPHOCYTES FOR ADOPTIVE IMMUNOTHERAPY | NORTHEASTERN UNIVERSITY (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100093728-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20040102626-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use cardiovascular preparations | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-05-27 | — | — | US | disclosed |
| EP-1417173-A1 | SUBSTITUTED 2-THIO-3, 5-DICYANO-4-PHENYL-6-AMINOPYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS | Bayer HealthCare AG (DE) | 2004-05-12 | — | — | EP | disclosed |
| EP-1377569-A1 | SUBSTITUTED 2-THIO-3,5-DICYANO-4-PHENYL-6-AMINOPYRIDINES WITH ADENOSINE RECEPTOR-BINDING ACTIVITY AND THEIR USE AS CARDIOVASCULAR PREPARATIONS | Bayer HealthCare AG (DE) | 2004-01-07 | — | — | EP | disclosed |
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | ASTELLAS PHARMA INC. (JP) | 2003-12-18 | — | — | US | disclosed |
| EP-1302463-A1 | MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| CN-1407971-A | Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof | BAYER AG (DE) | 2003-04-02 | — | — | CN | disclosed |
| WO-2003008384-A1 | SUBSTITUTED 2-THIO-3, 5-DICYANO-4-PHENYL-6-AMINOPYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS | BAYER HEALTHCARE AG (DE) | 2003-01-30 | — | — | WO | disclosed |
| WO-2002079195-A1 | SUBSTITUTED 2-THIO-3,5-DICYANO-4-PHENYL-6-AMINOPYRIDINES WITH ADENOSINE RECEPTOR-BINDING ACTIVITY AND THEIR USE AS CARDIOVASCULAR PREPARATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-10 | — | — | WO | disclosed |
| EP-1240145-A2 | SUBSTITUTED 2-THIO-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND THE USE THEREOF | Bayer Aktiengesellschaft (DE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001025210-A2 | SUBSTITUTED 2-THIO-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND THE USE THEREOF AS ADENOSINE RECEPTOR LIGANDS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102626-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use cardiovascular preparations | ADORA1, ADORA2A, ADORA3 | MAPT 4422/4885KDM4E 2921/4885HPGD 2393/4885 |
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | KCNN3, KCNN2, KCNN1 | MAPT 1220/4885KDM4E 369/4885HPGD 697/4885 |
| US-20100093728-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | MAPT 4459/4885KDM4E 4037/4885HPGD 1064/4885 |
| US-20140155401-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | MAPT 4459/4885KDM4E 4037/4885HPGD 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.